Prosecution Insights
Prosecution Insights
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (50%) |
| §112 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PURDY, KYLE A | 1 | 41.0% | +36.5% |
| SCHERBEL, TODD J | 1 | 76.2% | +52.3% |
| BOECKELMAN, JACOB A | 1 | 36.1% | +46.1% |
| HOBAN, MELISSA A | 1 | 63.0% | +13.1% |
| REGLAS, GEORGIANA C | 1 | 37.5% | +31.1% |
| COPPINS, JANET L | 1 | 72.9% | +25.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17080078 | ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASES | REGLAS, GEORGIANA C | 35d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16973987 | SCAFFOLD WITH ADHESIVE FOR ARTICULAR CARTILAGE REPAIR | HOBAN, MELISSA A | 25d overdue |
| 18197692 | METHOD FOR USE OF A DOUBLE-STRUCTURED TISSUE IMPLANT FOR TREATMENT OF TISSUE DEFECTS | SCHERBEL, TODD J | 9d overdue |
| 18503177 | Treatment of Neurological Disorder Using NHR | PURDY, KYLE A | 1d overdue |
| 17668511 | NEOCARTILAGE CONSTRUCTS USING UNIVERSAL CELLS | BOECKELMAN, JACOB A | 7d |
| 17080078 | ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASES | REGLAS, GEORGIANA C | 35d |
| 15963955 | NANOEMULSIONS WITH ANTI-INFLAMMATORY ACTIVITY | COPPINS, JANET L | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 3771 | 1 |
| 1655 | 1 |
| 3774 | 1 |
| 1651 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18503177 | Treatment of Neurological Disorder Using NHR | PURDY, KYLE A | 1611 | DP | Final Rejection | 1d overdue | Pending | Nov 06, 2023 |
| 18197692 | METHOD FOR USE OF A DOUBLE-STRUCTURED TISSUE IMPLANT FOR TREATMENT OF TISSUE DEFECTS | SCHERBEL, TODD J | 3771 | §103 | Final Rejection | 9d overdue | Pending | May 15, 2023 |
| 17668511 | NEOCARTILAGE CONSTRUCTS USING UNIVERSAL CELLS | BOECKELMAN, JACOB A | 1655 | §103 | Final Rejection | 7d | Pending | Feb 10, 2022 |
| 16973987 | SCAFFOLD WITH ADHESIVE FOR ARTICULAR CARTILAGE REPAIR | HOBAN, MELISSA A | 3774 | §103 | Non-Final OA | 25d overdue | Pending | Dec 10, 2020 |
| 17080078 | ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASES | REGLAS, GEORGIANA C | 1651 | §103§112 | Non-Final OA | 35d | Pending | Oct 26, 2020 |
| 15963955 | NANOEMULSIONS WITH ANTI-INFLAMMATORY ACTIVITY | COPPINS, JANET L | 1628 | §112 | Final Rejection | — | Pending | Apr 26, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial